Cargando…
Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies
Amyotrophic lateral sclerosis (ALS) is the most prominent motor neuron disease in humans. Its etiology consists of progressive motor neuron degeneration resulting in a rapid decline in motor function starting in the limbs or bulbar muscles and eventually fatally impairing central organs most typical...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128037/ https://www.ncbi.nlm.nih.gov/pubmed/35620141 http://dx.doi.org/10.1212/NXG.0000000000000669 |
_version_ | 1784712478027939840 |
---|---|
author | Smukowski, Samuel N. Maioli, Heather Latimer, Caitlin S. Bird, Thomas D. Jayadev, Suman Valdmanis, Paul N. |
author_facet | Smukowski, Samuel N. Maioli, Heather Latimer, Caitlin S. Bird, Thomas D. Jayadev, Suman Valdmanis, Paul N. |
author_sort | Smukowski, Samuel N. |
collection | PubMed |
description | Amyotrophic lateral sclerosis (ALS) is the most prominent motor neuron disease in humans. Its etiology consists of progressive motor neuron degeneration resulting in a rapid decline in motor function starting in the limbs or bulbar muscles and eventually fatally impairing central organs most typically resulting in loss of respiration. Pathogenic variants in 4 main genes, SOD1, TARDBP, FUS, and C9orf72, have been well characterized as causative for more than a decade now. However, these only account for a small fraction of all ALS cases. In this review, we highlight many additional variants that appear to be causative or confer increased risk for ALS, and we reflect on the technologies that have led to these discoveries. Next, we call attention to new challenges and opportunities for ALS and suggest next steps to increase our understanding of ALS genetics. Finally, we conclude with a synopsis of gene therapy paradigms and how increased understanding of ALS genetics can lead us to developing effective treatments. Ultimately, a consolidated update of the field can provide a launching point for researchers and clinicians to improve our search for ALS-related genes, defining pathogenic mechanisms, form diagnostics, and develop therapies. |
format | Online Article Text |
id | pubmed-9128037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-91280372022-05-25 Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies Smukowski, Samuel N. Maioli, Heather Latimer, Caitlin S. Bird, Thomas D. Jayadev, Suman Valdmanis, Paul N. Neurol Genet Review Amyotrophic lateral sclerosis (ALS) is the most prominent motor neuron disease in humans. Its etiology consists of progressive motor neuron degeneration resulting in a rapid decline in motor function starting in the limbs or bulbar muscles and eventually fatally impairing central organs most typically resulting in loss of respiration. Pathogenic variants in 4 main genes, SOD1, TARDBP, FUS, and C9orf72, have been well characterized as causative for more than a decade now. However, these only account for a small fraction of all ALS cases. In this review, we highlight many additional variants that appear to be causative or confer increased risk for ALS, and we reflect on the technologies that have led to these discoveries. Next, we call attention to new challenges and opportunities for ALS and suggest next steps to increase our understanding of ALS genetics. Finally, we conclude with a synopsis of gene therapy paradigms and how increased understanding of ALS genetics can lead us to developing effective treatments. Ultimately, a consolidated update of the field can provide a launching point for researchers and clinicians to improve our search for ALS-related genes, defining pathogenic mechanisms, form diagnostics, and develop therapies. Wolters Kluwer 2022-04-27 /pmc/articles/PMC9128037/ /pubmed/35620141 http://dx.doi.org/10.1212/NXG.0000000000000669 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Review Smukowski, Samuel N. Maioli, Heather Latimer, Caitlin S. Bird, Thomas D. Jayadev, Suman Valdmanis, Paul N. Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies |
title | Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies |
title_full | Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies |
title_fullStr | Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies |
title_full_unstemmed | Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies |
title_short | Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies |
title_sort | progress in amyotrophic lateral sclerosis gene discovery: reflecting on classic approaches and leveraging emerging technologies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128037/ https://www.ncbi.nlm.nih.gov/pubmed/35620141 http://dx.doi.org/10.1212/NXG.0000000000000669 |
work_keys_str_mv | AT smukowskisamueln progressinamyotrophiclateralsclerosisgenediscoveryreflectingonclassicapproachesandleveragingemergingtechnologies AT maioliheather progressinamyotrophiclateralsclerosisgenediscoveryreflectingonclassicapproachesandleveragingemergingtechnologies AT latimercaitlins progressinamyotrophiclateralsclerosisgenediscoveryreflectingonclassicapproachesandleveragingemergingtechnologies AT birdthomasd progressinamyotrophiclateralsclerosisgenediscoveryreflectingonclassicapproachesandleveragingemergingtechnologies AT jayadevsuman progressinamyotrophiclateralsclerosisgenediscoveryreflectingonclassicapproachesandleveragingemergingtechnologies AT valdmanispauln progressinamyotrophiclateralsclerosisgenediscoveryreflectingonclassicapproachesandleveragingemergingtechnologies |